Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Revenue (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Revenue for 11 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 78.79% to $23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.7 million through Dec 2025, up 16.92% year-over-year, with the annual reading at $67.7 million for FY2025, 16.92% up from the prior year.
  • Revenue for Q4 2025 was $23.0 million at Intellia Therapeutics, up from $13.8 million in the prior quarter.
  • The five-year high for Revenue was $39.5 million in Q4 2022, with the low at $300000.0 in Q3 2021.
  • Average Revenue over 5 years is $15.4 million, with a median of $13.3 million recorded in 2022.
  • The sharpest move saw Revenue plummeted 98.65% in 2021, then soared 4322.0% in 2022.
  • Over 5 years, Revenue stood at $37.9 million in 2021, then rose by 4.22% to $39.5 million in 2022, then tumbled by 69.64% to $12.0 million in 2023, then rose by 7.35% to $12.9 million in 2024, then soared by 78.79% to $23.0 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $23.0 million, $13.8 million, and $14.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.